Compare Super Micro Computer Inc (SMCI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Super Micro Computer Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Super Micro Computer Inc trades at $41.86 (market cap $28.10B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.5× Super Micro Computer Inc's market cap, and Super Micro Computer Inc is more actively traded (38,581,805 versus 1,487,944). Which is the better fit depends on your goals — on Pluang, investors hold Super Micro Computer Inc for 19 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SMCI | VRTX | |
|---|---|---|
Market Cap | $28.10B | $127.55B |
Volume | 38,581,805 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $55.04 | $557.96 |
52-Week Low | $20.53 | $407.37 |
Typical Hold Time | 19 Days | 120 Days |
Enterprise Value | $33.56B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Super Micro Computer (SMCI) trades at $42.77, down 4.85% on the day, with strong fundamental performance including three consecutive quarterly earnings beats and robust revenue growth projections. The stock shows a bullish technical signal with support at $42 and resistance at $44, while maintaining attractive valuation metrics with a P/E of 13.12 and P/S of 0.76. Recent news highlights AI-driven order growth and successful NVIDIA Vera Rubin platform shipments.
SMCI presents a compelling value opportunity with strong AI infrastructure positioning and solid financials, though investors face risks from ongoing DOJ investigation and AI market volatility. Analyst consensus leans cautious with 56% hold ratings despite $42.33 price target near current levels, suggesting balanced risk-reward profile for growth-oriented investors.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, with a bearish technical signal despite strong fundamentals. The company maintains dominant cystic fibrosis market position with 86% gross margins and 35% net income margin. Recent positive Phase 2b data for inaxaplin in kidney disease shows pipeline expansion potential. Revenue grew to $12.0B in 2025 with $3.95B net income, recovering from 2024's loss.
Analyst consensus remains strongly bullish with 84% buy ratings and $573.50 price target, representing 14% upside. Key risks include pipeline execution and competitive pressures. The stock offers growth potential through gene therapy expansion but faces volatility from clinical trial outcomes and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
